Abaloparatide Patent Expiration
Abaloparatide is Used for increasing bone density and reducing fracture risk in postmenopausal women and men with osteoporosis, as well as for detecting neutralizing antibodies. It was first introduced by Radius Health Inc
Abaloparatide Patents
Given below is the list of patents protecting Abaloparatide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tymlos | US11255842 | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog | Jan 10, 2040 | Radius |
| Tymlos | US11680942 | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog | Jan 10, 2040 | Radius |
| Tymlos | US10996208 | Abaloparatide formulations and methods of testing, storing, modifying, and using same | Apr 30, 2038 | Radius |
| Tymlos | US11782041 | Abaloparatide formulations and methods of testing, storing, modifying, and using same | Apr 30, 2038 | Radius |
| Tymlos | US11977067 | Abaloparatide formulations and methods of testing, storing, modifying, and using same | Apr 30, 2038 | Radius |
| Tymlos | US7803770 | Method of treating osteoporosis comprising administration of PTHrP analog | Apr 28, 2031 | Radius |
| Tymlos | USRE49444 | Method of treating osteoporosis comprising administration of PTHrP analog | Apr 28, 2031 | Radius |
| Tymlos | US8148333 | Stable composition comprising a PTHrP analogue | Nov 08, 2027 | Radius |
| Tymlos | US8748382 | Method of drug delivery for bone anabolic protein | Oct 03, 2027 | Radius |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Abaloparatide's patents.
Latest Legal Activities on Abaloparatide's Patents
Given below is the list recent legal activities going on the following patents of Abaloparatide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 11 Oct, 2023 | US11782041 |
| Recordation of Patent eGrant | 10 Oct, 2023 | US11782041 |
| Recordation of Patent Grant Mailed Critical | 10 Oct, 2023 | US11782041 |
| Sequence Moved to Public Database | 10 Oct, 2023 | US11782041 |
| Patent Issue Date Used in PTA Calculation Critical | 10 Oct, 2023 | US11782041 |
| Mail Patent eGrant Notification | 10 Oct, 2023 | US11782041 |
| Patent eGrant Notification | 10 Oct, 2023 | US11782041 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Oct, 2023 | US8148333 |
| Email Notification Critical | 21 Sep, 2023 | US11782041 |
| Issue Notification Mailed Critical | 20 Sep, 2023 | US11782041 |
Abaloparatide's Family Patents
